rs12720356 — TYK2 Ile684Ser

A missense variant in the TYK2 pseudokinase (JH2) domain that partially impairs TYK2 catalytic regulation, reducing IL-12-stimulated STAT4 signaling and conferring independent protection against rheumatoid arthritis, psoriasis, SLE, and type 1 diabetes

See your personal result for TYK2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TYK2 Ile684Ser — A Third Independent Brake on Autoimmune Signaling

TYK2 is the most genetically validated drug target in autoimmune disease today. Its pseudokinase (JH2) domain — the regulatory scaffold that controls the adjacent catalytic domain — is a hotspot for naturally occurring protective variants that reduce IL-12, IL-23, and type I interferon signaling without eliminating immune function. The Ile684Ser substitution (rs12720356) is the third and most common of three independent protein-coding protective signals in TYK2, and it provides some of the clearest evidence yet that TYK2 JH2 function is directly tunable by single amino acid changes.

Unlike rs34536443 (p.Pro1104Ala), which operates at the interface that couples the JH2 domain to the kinase (JH1) domain, Ile684Ser sits within the N-lobe of JH2 at a position that positions the αC helix for productive regulation of JH1. Replacing the rigid, hydrophobic isoleucine with a small, polar serine partially disrupts this structural arrangement — reducing but not abolishing TYK2's positive regulatory capacity. The net result is a hypomorphic TYK2 that retains sufficient antiviral and homeostatic signaling while measurably blunting the inflammatory amplification loops that drive autoimmune tissue damage.

The Mechanism

TYK2 mediates cytokine signaling downstream of the IL-12 receptor (activating JAK2-STAT4), IL-23 receptor (activating STAT3/STAT4), and type I interferon receptors IFNAR1/2 (activating JAK1-STAT1-STAT2). The JH2 pseudokinase domain acts as an allosteric regulator of the JH1 kinase domain — it both autoinhibits basal activity and potentiates the response to cytokine- driven activation.

Cytrzak-Gorczak et al. (2018)11 Cytrzak-Gorczak et al. (2018) demonstrated directly in human blood that I684S reduces IL-12-stimulated STAT4 phosphorylation22 STAT4 phosphorylation
STAT4 is a transcription factor activated by IL-12 signaling that drives Th1 differentiation and IFN-γ production; reduced pSTAT4 means blunted IL-12-driven T cell polarization toward the Th1 inflammatory phenotype in CD4+ and CD8+ memory T cells. Critically, this reduction was measurable in skin-homing CLA+33 CLA+
Cutaneous lymphocyte- associated antigen (CLA) marks T cells that home preferentially to skin, making them the relevant effector population in psoriasis T cells — the very immune cell subset responsible for psoriatic inflammation. Type I IFN-α signaling (STAT1/STAT2 pathway) is preserved because the JAK partner can compensate for reduced TYK2 JH2 regulatory capacity in that signaling context.

Fine-mapping of the TYK2 locus44 Fine-mapping of the TYK2 locus confirmed that I684S, A928V (rs35018800), and P1104A (rs34536443) sit on three different haplotype backgrounds, establishing their independence. Conditional analysis shows that even after accounting for the stronger P1104A and A928V signals, I684S retains an independent protective effect (OR 0.86, P=4.6×10⁻⁷ for RA), confirming it is a genuine causal variant rather than a tag for the others.

The Evidence

The foundational genetic evidence comes from Diogo et al. (2015)55 Diogo et al. (2015), who combined Immunochip dense genotyping, Exomechip genotyping, and targeted exon sequencing across 23,092 RA case/control + 18,409 additional samples. Three independent TYK2 coding signals emerged: P1104A (OR 0.66, P=2.3×10⁻²¹), A928V (OR 0.53, P=1.2×10⁻⁹), and I684S (OR 0.86, P=4.6×10⁻⁷). The same three variants also independently protected against SLE in the same study, supporting their pan-autoimmune relevance.

For psoriasis specifically, Sigurdardottir et al. (2018)66 Sigurdardottir et al. (2018) provided functional cellular evidence: the I684S C allele significantly reduced STAT4 phosphorylation following IL-12 stimulation, with the effect measurable in skin-homing memory T cells — a finding that bridges the genetic association to the cellular mechanism responsible for plaque formation.

The meta-analysis by Lee and Bae (2016)77 meta-analysis by Lee and Bae (2016), pooling 16,335 patients across 12 studies, confirmed protection for autoimmune rheumatic diseases in Caucasians (OR 0.812, 95% CI 0.661–0.997), though not in Asian populations — consistent with the variant's low frequency in East Asian ancestries. A 2019 study of Mexican patients with SLE88 2019 study of Mexican patients with SLE found strong protection at rs12720356 (OR 0.308 for childhood-onset, OR 0.250 for adult-onset), consistent with the Iberian origin of the C allele in admixed Latin American populations.

Practical Implications

With a European minor allele frequency of approximately 8%, I684S is more common than either A928V (~0.8%) or P1104A (~4%), making it the most population-accessible of the three independent TYK2 protective coding variants. About 15% of Europeans carry at least one C allele at rs12720356. Unlike P1104A — where the pharmacological copy (deucravacitinib) provided indirect evidence for a cancer immune-surveillance trade-off — no analogous cancer-risk signal has been reported for I684S carriers in the published literature.

For heterozygous AC carriers and for the rare CC homozygotes, this variant is relevant in the same clinical contexts as other TYK2 protective alleles: autoimmune workup interpretation, biologic therapy consideration, and family-history counseling for RA, SLE, psoriasis, and T1D. If a TYK2 inhibitor such as deucravacitinib is prescribed, the I684S allele contributes an independent layer of baseline TYK2 attenuation that a prescriber should be aware of.

Interactions

rs12720356 is one of three independent TYK2 protective coding variants confirmed by haplotype analysis to reside on separate haplotype backgrounds (Diogo et al. 2015). The other two are rs34536443 (P1104A, MAF ~4% in Europeans) and rs35018800 (A928V, MAF ~0.8% in Europeans). Individuals carrying C alleles at more than one of these three loci have multiple independent layers of TYK2 JH2 attenuation.

rs2304256 (V362F) — also in TYK2 — operates through a completely different mechanism (exon 8 splicing and FERM domain receptor binding), and fine-mapping has resolved99 fine-mapping has resolved that the rs2304256 association signal in SLE and RA GWAS is largely driven by imperfect linkage disequilibrium with the actual causal coding variants, including I684S. The two variants are functionally and genetically independent.

Beyond TYK2, the I684S protective effect acts within the same autoimmune genetic architecture as PTPN22 (rs2476601, T cell receptor threshold) and CTLA4 (rs3087243, costimulation threshold) — variants that modulate T cell activation at different checkpoints and likely confer additive protection when co-inherited with protective TYK2 alleles.

Drug Interactions

deucravacitinib dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

AA No I684S Protection Normal

Common genotype — standard TYK2 Ile684 signaling, no I684S-mediated autoimmune protection

The AA genotype represents the GRCh38 reference allele configuration (Ile684 in TYK2 pseudokinase domain). TYK2 JH2 in Ile684 carriers can positively regulate the JH1 kinase domain at full capacity, supporting normal IL-12-STAT4 and IL-23-STAT3/STAT4 amplification. Your autoimmune susceptibility at this locus is baseline — neither elevated nor reduced by rs12720356. Other loci (HLA class II, PTPN22 rs2476601, CTLA4 rs3087243, and the other TYK2 protective variants rs34536443 and rs35018800) determine your individual risk profile.

AC Partial I684S Protection Beneficial

One protective Ser684 allele — partial reduction in IL-12-STAT4 signaling and autoimmune risk

The heterozygous AC state produces a mixture of Ile684 (normal) and Ser684 (hypomorphic) TYK2 protein. The combined result is intermediate JH2 regulatory activity — sufficient to measurably reduce IL-12-stimulated STAT4 phosphorylation in skin-homing T cells (documented by Sigurdardottir et al. 2018), but not the maximal attenuation seen in CC homozygotes. The I684S effect is mechanistically independent of P1104A (rs34536443) and A928V (rs35018800), so carrying I684S provides protection that stacks additively with those other TYK2 protective variants if present.

The variant appears most clinically significant in European ancestry populations; in East Asian populations it is extremely rare, limiting its contribution to autoimmune protection in those groups.

CC Full I684S Protection Beneficial

Two protective Ser684 alleles — strongest I684S-mediated reduction in TYK2 STAT4 signaling

The CC homozygote produces only Ser684 TYK2 protein. The JH2 N-lobe substitution is on both chromosomes, producing maximal disruption of the αC-helix positioning that normally enables JH2 to positively regulate JH1 kinase activity. In human T cell studies, this translates to the greatest reduction in IL-12-stimulated STAT4 phosphorylation — including in skin-homing CLA+ T cells — meaning reduced Th1 polarization in the tissues most relevant to psoriatic and rheumatoid autoimmunity.

Unlike TYK2 P1104A (rs34536443 CC), no published data associates I684S homozygosity with a cancer immune-surveillance trade-off (elevated lung cancer or NHL odds). The I684S effect on IFN-α-mediated STAT1/STAT2 signaling is minimal because JAK partner compensation preserves that pathway, limiting the antiviral immunity trade-off that would be expected from more complete TYK2 loss of function.